Nasdaq

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

CAMBRIDGE, Mass., July 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
Seeking Alpha

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 ...
Medindia

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

CAMBRIDGE, Mass., Sept. 13, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
Investing

Nuvalent's NVL-655 shows promise in ALK-positive lung cancer

CAMBRIDGE, Mass. - Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company, has announced the publication of a manuscript in Cancer Discovery (NASDAQ:WBD) journal, presenting the ...
Investing

Nuvalent advances NVL-655 in phase 2 trial for lung cancer

NVL-655 is a novel, brain-penetrant, ALK-selective tyrosine kinase inhibitor (TKI) developed to address emergent treatment resistance and brain metastases while minimizing off-target central nervous ...
Seeking Alpha

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Publication provides comprehensive assessment of NVL-655's preclinical activity and includes preliminary clinical case studies CAMBRIDGE, Mass., Sept. 13, 2024 /PRNewswire/ -- Nuvalent, Inc. (NUVL) ...